公开(公告)号：US20130274211A1

公开(公告)日：2013-10-17

申请号：US13633638

申请日：2012-10-02

Applicant: Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Sanjoy Mullick ,  Manu Jaggi ,  Manoj Kumar Singh ,  Mukesh Kumar ,  Deepak Prusthy ,  Pawan Kumar Gupta ,  Rajendran Praveen ,  Shobhit Singh

Inventor： Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Sanjoy Mullick ,  Manu Jaggi ,  Manoj Kumar Singh ,  Mukesh Kumar ,  Deepak Prusthy ,  Pawan Kumar Gupta ,  Rajendran Praveen ,  Shobhit Singh

IPC: A61K47/32

CPC classification number: A61K47/32 ,  C08F220/56 ,  C08F222/12 ,  C08F222/385 ,  C08F226/10

Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidne (VP), N-Isopropylactylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

Abstract translation: 本发明涉及式（I）的生物相容性，不可生物降解的和无毒的聚合物，其包含三种单体单元，其选自1-乙烯基吡咯烷酮（VP），N-异丙基丙烯酰胺（NIPAM）和马来酸酐的酯和 与双官能乙烯基衍生物交联的聚乙二醇（MPEG），其纯度高，基本上不含有毒的单体污染物及其制备方法。 本发明还涉及难溶于水的药物或包含本发明聚合物的化合物的纳米颗粒药物组合物，其对于有需要的患者的床边给药是安全的，毒性较小且方便的。 此外，本发明涉及用于制备难溶于水的药物或化合物的纳米颗粒药物组合物的高选择性方法。

公开(公告)号：US20070203248A1

公开(公告)日：2007-08-30

申请号：US11789974

申请日：2007-04-26

Applicant: Rama Mukherjee ,  Anu Singh ,  Kakali Dutta ,  G.C. Maickap ,  Anil Shukla ,  Dhiraj Khattar ,  Anand Burman

Inventor： Rama Mukherjee ,  Anu Singh ,  Kakali Dutta ,  G.C. Maickap ,  Anil Shukla ,  Dhiraj Khattar ,  Anand Burman

IPC: A61K31/137

CPC classification number: A61K31/4045 ,  A61K31/00 ,  A61K31/704 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions comprising 5-Methoxytryptamine or a salt thereof for the prevention and/or treatment of mammalian cardiac tissue damage. 5-Methoxytryptamine and the salts thereof act as free radical scavengers in the prevention and/or treatment of mammalian cardiac tissue damage mediated by free oxygen radicals.

Abstract translation: 本发明涉及包含5-甲氧基色胺或其盐的药物组合物，用于预防和/或治疗哺乳动物心脏组织损伤。 5-甲氧基色胺及其盐作为自由基清除剂，用于预防和/或治疗由游离氧自由基介导的哺乳动物心脏组织损伤。

公开(公告)号：US06596755B2

公开(公告)日：2003-07-22

申请号：US10187422

申请日：2002-07-01

Applicant: Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Mukesh Kumar

Inventor： Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Mukesh Kumar

IPC: A61K3140

CPC classification number: A61K9/0095 ,  A61K9/145 ,  A61K9/4858 ,  A61K31/175 ,  A61K31/4015 ,  A61K47/542

Abstract: The invention relates to an oral formulation of methylglyoxal and/or its imino acid conjugates for human use and methods for preparing the compositions. Particularly, the invention relates to compositions comprising methylglyoxal and more particularly, imino acid conjugates of methylglyoxal. The present invention also relates to formulations of methylglyoxal and imino acid conjugates of methylglyoxal that can be used for the treatment and suppression of malignant diseases including but not limited to the cancers of Colon, Prostate, Pancreas, Lung, Oral cavity, Glioblastoma, and Leukemia.

公开(公告)号：US06322817B1

公开(公告)日：2001-11-27

申请号：US09401927

申请日：1999-09-23

Applicant: Amarnath Maitra ,  Sanjeeb Kumar Sahoo ,  Prasanta Kumar Ghosh ,  Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Mukesh Kumar ,  Soumendu Paul

Inventor： Amarnath Maitra ,  Sanjeeb Kumar Sahoo ,  Prasanta Kumar Ghosh ,  Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Mukesh Kumar ,  Soumendu Paul

IPC: A61K4730

CPC classification number: A61K9/5138 ,  A61K9/1075 ,  A61K9/5146 ,  A61K9/5192 ,  A61K31/337 ,  Y10S977/906

Abstract: This invention relates to pharmaceutical formulations of paclitaxel, its derivatives or analogs entrapped into nanoparticles of co-polymeric micelles, a process for preparing the same and the use thereof.

Abstract translation: 本发明涉及包埋在共聚合胶束纳米颗粒中的紫杉醇，其衍生物或类似物的药物制剂，其制备方法及其用途。

公开(公告)号：US08338562B2

公开(公告)日：2012-12-25

申请号：US12159310

申请日：2006-12-26

Applicant: Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Sanjoy Mullick ,  Manu Jaggi ,  Manoj Kumar Singh ,  Mukesh Kumar ,  Deepak Prusthy ,  Pawan Kumar Gupta ,  Rajendran Praveen ,  Shobhit Singh

Inventor： Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Sanjoy Mullick ,  Manu Jaggi ,  Manoj Kumar Singh ,  Mukesh Kumar ,  Deepak Prusthy ,  Pawan Kumar Gupta ,  Rajendran Praveen ,  Shobhit Singh

IPC: C08F26/00

CPC classification number: A61K47/32 ,  C08F220/56 ,  C08F222/12 ,  C08F222/385 ,  C08F226/10

Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

Abstract translation: 本发明涉及式（I）的生物相容性，不可生物降解的和无毒的聚合物，其包含三种单体单元，其选自1-乙烯基吡咯烷酮（VP），N-异丙基丙烯酰胺（NIPAM）和马来酸酐的酯和 与双官能乙烯基衍生物交联的聚乙二醇（MPEG），其纯度高，基本上不含有毒的单体污染物及其制备方法。 本发明还涉及难溶于水的药物或包含本发明聚合物的化合物的纳米颗粒药物组合物，其对于有需要的患者的床边给药是安全的，毒性较小且方便的。 此外，本发明涉及用于制备难溶于水的药物或化合物的纳米颗粒药物组合物的高选择性方法。

公开(公告)号：US20090318661A1

公开(公告)日：2009-12-24

申请号：US12159310

申请日：2006-12-26

Applicant: Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Sanjoy Mullick ,  Manu Jaggi ,  Manoj Kumar Singh ,  Mukesh Kumar ,  Deepak Prusthy ,  Pawan Kumar Gupta ,  Rajendran Praveen ,  Shobhit Singh

Inventor： Anand C. Burman ,  Rama Mukherjee ,  Dhiraj Khattar ,  Sanjoy Mullick ,  Manu Jaggi ,  Manoj Kumar Singh ,  Mukesh Kumar ,  Deepak Prusthy ,  Pawan Kumar Gupta ,  Rajendran Praveen ,  Shobhit Singh

IPC: C08G61/04

CPC classification number: A61K47/32 ,  C08F220/56 ,  C08F222/12 ,  C08F222/385 ,  C08F226/10

Abstract: The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside administration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

Abstract translation: 本发明涉及式（I）的生物相容性，不可生物降解的和无毒的聚合物，其包含三种单体单元，其选自1-乙烯基吡咯烷酮（VP），N-异丙基丙烯酰胺（NIPAM）和马来酸酐的酯和 与双官能乙烯基衍生物交联的聚乙二醇（MPEG），其纯度高，基本上不含有毒的单体污染物及其制备方法。 本发明还涉及难溶于水的药物或包含本发明聚合物的化合物的纳米颗粒药物组合物，其对于有需要的患者的床边给药是安全的，毒性较小且方便的。 此外，本发明涉及用于制备难溶于水的药物或化合物的纳米颗粒药物组合物的高选择性方法。

公开(公告)号：US20090017105A1

公开(公告)日：2009-01-15

申请号：US12045958

申请日：2008-03-11

Applicant: Dhiraj Khattar ,  Mukesh Kumar ,  Rama Mukherjee ,  Anand C. Burman ,  Minakshi Garg ,  Manu Jaggi ,  Anu T. Singh ,  Anshumali Awasthi

Inventor： Dhiraj Khattar ,  Mukesh Kumar ,  Rama Mukherjee ,  Anand C. Burman ,  Minakshi Garg ,  Manu Jaggi ,  Anu T. Singh ,  Anshumali Awasthi

IPC: A61K9/127 ,  A61P35/00

CPC classification number: A61K31/337 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/1277

Abstract: Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ≧95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.

Abstract translation: 水溶性差的药物和化合物的浓缩物或前体组合物，包含一种或多种形成膜的脂质，膜稳定剂，在合适的载体中，并且任选地含有聚乙二醇（PEG） - 偶联的磷脂或其混合物 ，任选地含有药学上可接受的赋形剂如抗氧化剂，缓冲剂，酸化剂等，其具有优异的长期稳定性。 促乳素体组合物的浓缩物立即形成所述水难溶性药物和化合物的脂质体，其快速注射至稀释液体，如此获得的脂质体组合物，其特征在于物理稳定性超过24小时，> = 95％药物包封并具有 粒度直径小于100nm。 如此获得的脂质体组合物可以进一步直接施用于需要治疗不良水溶性药物和化合物的患者。

公开(公告)号：US20060217350A1

公开(公告)日：2006-09-28

申请号：US11245389

申请日：2005-10-06

Applicant: Dhiraj Khattar ,  Manish Grover ,  Mukesh Kumar ,  Prasanna Kumar Srinivasa Jonnala ,  Shobhit Singh ,  Rama Mukherjee ,  Anand Burman

Inventor： Dhiraj Khattar ,  Manish Grover ,  Mukesh Kumar ,  Prasanna Kumar Srinivasa Jonnala ,  Shobhit Singh ,  Rama Mukherjee ,  Anand Burman

IPC: A61K31/66

CPC classification number: A61K9/0019 ,  A61K9/08 ,  A61K31/663 ,  A61K47/26

Abstract: A stable pharmaceutical composition comprising a solution of disodium pamidronate in an aqueous solvent and a process for the preparation thereof. The solution of disodium pamidronate is free of particulate matter and has an alkaline pH. The process for preparation of the stable pharmaceutical composition comprises adding disodium pamidronate and optionally a sugar into an aqueous solvent; heating the said mixture at a temperature in the range of 50° C. to 90° C. to obtain a clear solution. It is cooled to ambient temperature, filtered, filled and stored in a conventional and untreated glass container and sealed with normal elastomeric closure. The sealed container is sterilized by steam sterilization.

Abstract translation: 一种稳定的药物组合物，其包含在水性溶剂中的帕米膦酸二钠溶液及其制备方法。 帕米膦酸二钠的溶液不含颗粒物质，具有碱性pH。 制备稳定的药物组合物的方法包括将帕米膦酸二钠和任选的糖加入到含水溶剂中; 在50℃至90℃的温度下加热所述混合物以获得澄清溶液。 将其冷却至环境温度，过滤，填充并储存在常规和未处理的玻璃容器中并用正常弹性封闭物密封。 密封容器通过蒸汽灭菌灭菌。

公开(公告)号：US07699987B2

公开(公告)日：2010-04-20

申请号：US11449476

申请日：2006-06-08

Applicant: Anand C. Burman ,  Rama Mukherjee ,  Dinesh Kumar ,  Dhiraj Khattar ,  Mukesh Kumar ,  Praveen Khullar ,  Perundurai S. Srinivasan ,  Rajesh Srivastava

Inventor： Anand C. Burman ,  Rama Mukherjee ,  Dinesh Kumar ,  Dhiraj Khattar ,  Mukesh Kumar ,  Praveen Khullar ,  Perundurai S. Srinivasan ,  Rajesh Srivastava

IPC: B01D15/08

CPC classification number: C07D305/14 ,  A61K47/44 ,  B01D15/325 ,  B01J20/287

Abstract: A stabilized pharmaceutical composition of anticancer drug and a solvent like Polyethoxylated castor oil (cremophor) also containing any other suitable solubilizer suitable for human administration like dehydrated alcohol, is disclosed. Compositions prepared using this purified polyethoxylated castor oil enhance the stability of paclitaxel in such compositions.

Abstract translation: 公开了一种稳定的抗癌药物和溶剂，如聚乙氧基化蓖麻油（cremophor）的药物组合物，其也含有适于人类给药的任何其它合适的增溶剂如脱水醇。 使用该纯化的聚乙氧基化蓖麻油制备的组合物增强紫杉醇在这些组合物中的稳定性。

公开(公告)号：US20050020666A1

公开(公告)日：2005-01-27

申请号：US10627398

申请日：2003-07-25

Applicant: Rama Mukherjee ,  Anu Singh ,  Kakali Dutta ,  G.C Maickap ,  Anil Shukla ,  Dhiraj Khattar ,  Anand Burman

Inventor： Rama Mukherjee ,  Anu Singh ,  Kakali Dutta ,  G.C Maickap ,  Anil Shukla ,  Dhiraj Khattar ,  Anand Burman

IPC: A61K31/00 ,  A61K31/4045 ,  A61K31/704 ,  A61P9/10 ,  A61P39/06 ,  A61K31/405

CPC classification number: A61K31/4045 ,  A61K31/00 ,  A61K31/704 ,  A61K2300/00

Abstract: The invention relates to pharmaceutical compositions comprising 5-Methoxytryptamine or a salt thereof for the prevention and/or treatment of mammalian cardiac tissue damage. 5-Methoxytryptamine and the salts thereof act as free radical scavengers in the prevention and/or treatment of mammalian cardiac tissue damage mediated by free oxygen radicals.

Abstract translation: 本发明涉及包含5-甲氧基色胺或其盐的药物组合物，用于预防和/或治疗哺乳动物心脏组织损伤。 5-甲氧基色胺及其盐作为自由基清除剂，用于预防和/或治疗由游离氧自由基介导的哺乳动物心脏组织损伤。